Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
8.17
+0.01 (0.12%)
At close: Mar 6, 2026, 4:00 PM EST
8.02
-0.15 (-1.84%)
After-hours: Mar 6, 2026, 6:58 PM EST
Fulcrum Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Fulcrum Therapeutics stock have an average target of 16.38, with a low estimate of 7.00 and a high estimate of 25. The average target predicts an increase of 100.49% from the current stock price of 8.17.
Analyst Consensus: Buy
* Price targets were last updated on Dec 11, 2025.
Analyst Ratings
The average analyst rating for Fulcrum Therapeutics stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $14 → $18 | Strong Buy | Maintains | $14 → $18 | +120.32% | Dec 11, 2025 |
| B of A Securities | B of A Securities | Sell Maintains $6 → $7 | Sell | Maintains | $6 → $7 | -14.32% | Dec 9, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $7 → $10 | Hold | Maintains | $7 → $10 | +22.40% | Dec 8, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $15 → $24 | Buy | Maintains | $15 → $24 | +193.76% | Dec 8, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $16 → $23 | Buy | Reiterates | $16 → $23 | +181.52% | Dec 8, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.31
from -1.18
EPS Next Year
-1.60
from -1.31
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.96 | -1.13 | |||
| Avg | -1.31 | -1.60 | |||
| Low | -1.67 | -2.07 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.